{
  "docId": "019de077-7395-77e8-a759-85ee5ceb6441",
  "docSlug": "d10c7e5183f0665a04c27575aa737d7a",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 42,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "Slide 19 of a presentation; includes revenue charts for CVRM and R&I segments and a list of key Q4 2024 dynamics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-7395-77e8-a759-85ee5ceb6441/19",
  "deckHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441",
  "deckJsonHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441.json",
  "deckAnchorHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.28,
        "x": 0.38,
        "y": 0.25
      },
      "kind": "chart",
      "text": "R&I Revenue 2023-2024",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0042c4ac-6852-4831-9d57-363ed84630da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.28,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "CVRM Revenue 2023-2024",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e58fbe4-0fb4-4e02-884c-c4049525c8b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "list",
      "text": "Q4 2024: key dynamics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "294e16df-7117-4399-9438-62049020242f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "All growth rates at CER. Appendix: Glossary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59741749-e140-494d-94f9-c46f4c003e6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "Total Revenue $21.9bn, +21%, strong momentum from multiple medicines",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c29e6519-6ef9-418f-a740-472b7ed8726b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "BioPharmaceuticals – FY and Q4 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "257d7f12-2fa7-4f9d-bacd-644007870f29",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 17,
      "beatId": "e47ffa97-7762-483f-b704-045948218cac",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "The slides use visual aids and key messages to help the audience visualize the company's growth momentum and future prospects.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 17,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0642f45f-f82f-4cf0-ac20-36b05c74bfb1",
      "evidence": "The slides use the golden circle framework to explain the company's growth momentum and future prospects.",
      "position": 1,
      "objective": "Why is AstraZeneca's growth sustainable?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}